Clinical cure ‐ not measured · People with fungal infections of the toenails
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with complete cure · People with fungal infections of the toenails
Efinaconazole 10% solution leads to higher complete cure: 40 to 52 weeks compared with vehicle (high certainty).
1 finding from 1 review
Adverse events (collected over the course of the studies; they are not measured/reported for specific time points) · People with fungal infections of the toenails
Efinaconazole 10% solution leads to higher adverse events (collected over the course of the studies; they are… compared with vehicle (high certainty).
1 finding from 1 review
Mycological cure · People with fungal infections of the toenails
Efinaconazole 10% solution probably leads to higher mycological cure: 40 to 52 weeks compared with vehicle (moderate certainty).
1 finding from 1 review
Cure · People with fungal infections of the toenails
Efinaconazole 10% solution leads to higher clinical cure: 40 to 52 weeks compared with vehicle (high certainty).
1 finding from 1 review
Proportion of participants with complete cure · People with fungal infections of the toenails
Tavaborole 5% solution probably leads to higher complete cure: 52 weeks compared with vehicle (moderate certainty).
1 finding from 1 review
Intervention not reported
Improvement in symptoms, reported by the child or by their parents/carers, preferably measured by a validated tool, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis
1 finding from 1 review
Intervention not reported
Elimination of all clinical signs of ocular surface inflammation ('complete success'), preferably measured by a composite grading system, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Improvement of clinical signs of ocular surface inflammation ('partial success'), preferably measured by a composite grading system, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis
1 finding from 1 review
no estimate extracted
137 participants
Very low
Intervention not reported
Change from baseline in best corrected visual acuity in affected eye(s) in logMAR · children with blepharokeratoconjunctivitis
1 finding from 1 review
Intervention not reported
Uncontrolled or poorly controlled disease progression due to treatment failure, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse effects of medication, at any time during treatment · children with blepharokeratoconjunctivitis
1 finding from 1 review
Intervention not reported
Quality of life · children with blepharokeratoconjunctivitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants achieving 'clearance' by IGA · scalp psoriasis
Steroid probably leads to higher number of participants achieving 'clearance' by IGA compared with vitamin D (moderate certainty).
1 finding from 1 review
Number of participants achieving 'response' by PGA · scalp psoriasis
Steroid plus vitamin D leads to higher number of participants achieving 'response' by PGA compared with steroid (high certainty).
1 finding from 1 review
Number of participants achieving 'clearance' by IGA · scalp psoriasis
Steroid plus vitamin D leads to higher number of participants achieving 'clearance' by IGA compared with vitamin D (high certainty).
1 finding from 1 review
Number of participants achieving 'response' by IGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'response' by IGA compared with vitamin D (moderate certainty).
1 finding from 1 review
Quality of life · scalp psoriasis
1 finding from 1 review
Number of participants withdrawing due to adverse events (AE) · scalp psoriasis
Steroid plus vitamin D leads to lower number of participants withdrawing due to adverse events compared with vitamin D (high certainty).
1 finding from 1 review
Number of participants achieving 'response' by PGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'response' by PGA compared with vitamin D (moderate certainty).
1 finding from 1 review